Conference Coverage
Conference Coverage
VOYAGER PAD: Clopidogrel adds no benefit to rivaroxaban plus aspirin after PAD interventions
Analysis of VOYAGER PAD results showed no benefit with clopidogrel, but patients on three antithrombotics had more bleeding episodes.
Conference Coverage
Alirocumab effective in homozygous FH
“We’re not getting most patients to goal, but we’re certainly getting them closer to goal.” – Dr. Dirk Blom
Conference Coverage
Larger absolute rivaroxaban benefit in diabetes: COMPASS
Conference Coverage
VICTORIA: Vericiguat seen as novel success in tough-to-treat, high-risk heart failure
The relative risk reduction was modest, but experts say the benefit in absolute terms was remarkable for already well-treated patients.
Conference Coverage
TAILOR-PCI: Clopidogrel genotyping trial narrowly misses endpoint
The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but experts felt that it still should change practice...
Conference Coverage
Primordial cardiovascular prevention draws closer
“LDL and blood pressure, which are modifiable, may be more powerful determinants of lifetime risk than polygenic predisposition.” – Dr. Brian A....
Conference Coverage
Before the COVID-19 surge hits your facility, take steps to boost capacity
Communication about resource allocation can ease workforce anxiety amid the coronavirus pandemic.
Conference Coverage
Dramatic rise in hypertension-related deaths in the United States
The ‘alarming’ increase in hypertension-related deaths between 2007 and 2017, was particularly prominent in the rural South.
Conference Coverage
African Americans with SLE face increased risk of CVD hospitalizations
PHOENIX – “Our next steps include examining potential reasons for these disparities, such as looking at primary care patterns over time, SLE...
Conference Coverage
PARAGON-HF: Optimal systolic pressure in HFpEF is 120-129 mm Hg
Conference Coverage
Testosterone therapy linked to CV risk in men with HIV